Abstract
Coronary heart disease (CHD) continues to be the leading cause of death among women in the United States. Evidence‐based guidelines of the American Heart Association (AHA) offer clinicians recommendations for preventing CHD in women delineating particular lifestyle, risk factor, and pharmacologic interventions. Cigarette smoking, physical inactivity, inappropriate diet, dyslipidemia, hypertension, diabetes mellitus, and metabolic syndrome contribute to the risk of CHD in women, as in men. Lifestyle interventions substantially reduce that risk. Many women, however, require pharmacotherapy to control hypertension, dyslipidemia, and diabetes to levels required for decreasing risk. New findings from clinical trials featuring women may enhance their CHD risk prediction and treatment. However, high coronary risk in many women continues to be underrecognized, and women remain undertreated with statins and other therapeutic agents. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: cardiovascular disease, coronary heart disease (CHD), prevention, women
Full Text
The Full Text of this article is available as a PDF (124.8 KB).
References
- 1. Wenger NK: Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 2003; 46: 199–229. [DOI] [PubMed] [Google Scholar]
- 2. American Heart Association : Heart Disease and Stroke Statistics—2006 Update. Dallas, TX: American Heart Association; 2006. [Google Scholar]
- 3. Ajani UA, Ford ES: Has the risk for coronary heart disease changed among U.S. adults? J Am Coll Cardiol 2006; 48: 1177–1182. [DOI] [PubMed] [Google Scholar]
- 4. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra‐Strobos N, et al.: Evidence‐based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109: 672–693. [DOI] [PubMed] [Google Scholar]
- 5. Department of Health and Human Services . Results from the 2005 National Survey on Drug Use and Health: national findings, http://oas.samhsa.gov/nsduh/2k5nsduh/2k5results.pdf Accessed December 5, 2006.
- 6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. Circulation 2002; 106: 3143–3421. [PubMed] [Google Scholar]
- 7. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, et al, for the Coordinating Committee of the National Cholesterol Education Program : Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239. [DOI] [PubMed] [Google Scholar]
- 8. Ridker PM, Cook NR, Lee I‐M, Gordon D, Gaziano JM, et al.: A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304. [DOI] [PubMed] [Google Scholar]
- 9. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE: Non‐HDL cholesterol, apolipoproteins A‐I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326–333. [DOI] [PubMed] [Google Scholar]
- 10. Cook NR, Buring JE, Ridker PM: The effect of including C‐reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006; 145: 21–29. [DOI] [PubMed] [Google Scholar]
- 11. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett‐Connor E, et al.: Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004; 63: 658–663. [DOI] [PubMed] [Google Scholar]
- 12. Bibbins‐Domingo K, Lin F, Vittinghoff E, Barrett‐Connor E, Hulley SB, et al.: Predictors of heart failure among women with coronary disease. Circulation 2004; 110: 1424–1430. [DOI] [PubMed] [Google Scholar]
- 13. Diabetes Prevention Program Research Group : Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, et al, for the Diabetes Prevention Program Research Group : Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29: 2102–2107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444–2449. [DOI] [PubMed] [Google Scholar]
- 16. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta‐analysis. Am J Med 2006; 119: 812–819. [DOI] [PubMed] [Google Scholar]
- 17. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, et al, for the NORVIT Trial Investigators : Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578–1588. [DOI] [PubMed] [Google Scholar]
- 18. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators : Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567–1577. [DOI] [PubMed] [Google Scholar]
- 19. Lee I‐M, Cook NR, Gaziano JM, Gordon D, Ridker PM, et al.: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 56–65. [DOI] [PubMed] [Google Scholar]
- 20. Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333. [DOI] [PubMed] [Google Scholar]
- 21. The Women's Health Initiative Steering Committee : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701–1712. [DOI] [PubMed] [Google Scholar]
- 22. Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, et al.: Effect of estrogen therapy on gallbladder disease. JAMA 2005; 293: 330–339. [DOI] [PubMed] [Google Scholar]
- 23. Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, et al, for the Women's Health Initiative Investigators : Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404–414. [DOI] [PubMed] [Google Scholar]
- 24. Ouyang P, Michos ED, Karas RH: Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J Am Coll Cardiol 2006; 47: 1741–1753. [DOI] [PubMed] [Google Scholar]
- 25. Barrett‐Connor E, Mosca L, Collins P, Geiger MJ, Grady D, et al, for the Raloxifene Use for The Heart (RUTH) Trial Investigators : Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–137. [DOI] [PubMed] [Google Scholar]
- 26. Smith SC, Allen J, Blair SN: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 Update. Endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47: 2130–2139. [DOI] [PubMed] [Google Scholar]
- 27. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, et al, on behalf of the PROSPER study group : Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630. [DOI] [PubMed] [Google Scholar]
- 28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002; 288: 2998–3007. [DOI] [PubMed] [Google Scholar]
- 29. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V: Female‐specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005; 26: 1585–1595. [DOI] [PubMed] [Google Scholar]
- 30. Heart Protection Study Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high‐risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7–22.12114036 [Google Scholar]
- 31. Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V, on behalf of the TNT Steering Committee and Investigators : Effect of 80 mg versus 10 mg of atorvastatin in women and men and stable coronary heart disease. Circulation 2005; 112(suppl II): II–819. [Google Scholar]
- 32. Welty FK, Lewis SJ, Friday KE, Cain VA, Gold A: Women achieve American Heart Association optimal lipid goals with statin therapy. Circulation 2005; 111: E–62. [Google Scholar]
- 33. Ford ES, Mokdad AH, Giles WH, Mensah GA: Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185–2189. [DOI] [PubMed] [Google Scholar]
- 34. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, et al, for the NEPTUNE II Steering Committee : Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey. Am Heart J 2006; 152: 976–981. [DOI] [PubMed] [Google Scholar]
- 35. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E: Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005; 28: 514–520. [DOI] [PubMed] [Google Scholar]
- 36. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, et al, for the CRUSADE Investigators : Gender disparities in the diagnosis and treatment of non‐ST‐segment elevation acute coronary syndromes: large‐scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005; 45: 832–837. [DOI] [PubMed] [Google Scholar]
- 37. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291–1297. [DOI] [PubMed] [Google Scholar]